CDKL5 deficiency disorder (CDD) is caused by loss-of-function changes in the CDKL5 gene, which makes a protein essential for building and fine-tuning the connections between brain cells. CDD is X-linked and affects mostly girls, and because seizures typically begin within the first few months of life and often resist standard medications, the condition is usually described, first and foremost, as a catastrophic epilepsy syndrome. But 2026 research across several large caregiver-reported and clinical studies reveals a fuller picture: sleep disruption and behavioral burden shape daily life for affected individuals and their families just as much as seizure counts do, and newly understood biology points toward treatments that could reach beyond seizure control altogether.
What CDKL5 Does in the Developing Brain
The CDKL5 protein's job goes well beyond simply raising or lowering seizure threshold. A 2026 study found that CDKL5 forms molecular condensates with PSD95, a key scaffolding protein at the synapse, through a process called liquid-liquid phase separation; this process recruits another protein needed for dendritic spines, the tiny structures where brain cells form new connections, to grow and strengthen. Disease-causing CDKL5 mutations impair this phase-separation process directly, helping explain why CDD causes both severe epilepsy and profound developmental impairment together, rather than epilepsy that simply happens to delay development. Clinically, a 2026 observational study following 112 patients with CDD (93% female, mean age 8.3 years, ranging from under 1 year old to 28 years old) found that seizures typically begin by 1.5 months of age, and 82% of patients had more than 16 seizures within their first 28 days in the study. Patients used an average of 2.6 antiseizure medications, yet a standard motor function measure showed a floor effect in crawling, standing, and walking across every age group, meaning most patients do not gain these skills even as they grow older.
Living With CDKL5 Deficiency Disorder: What Helps
- Track sleep and gut health alongside seizures. Because constipation and seizure patterns are both closely tied to sleep disruption in CDD, ask your care team to monitor bowel health and nighttime seizures as closely as daytime seizure counts, since treating these modifiable factors can meaningfully improve sleep quality.
- Expect non-seizure benefits to matter as much as seizure counts. Caregivers in a 2026 treatment study continued a therapy even after its seizure-reducing effect faded, because they valued improvements in alertness, mood, and engagement; pay attention to these quality-of-life changes, not just seizure frequency, when evaluating any new treatment.
- Seek developmental support regardless of seizure control. Because CDKL5's role in brain development is independent of seizure activity, developmental, communication, and physical therapies remain valuable even when seizures are well controlled or, conversely, difficult to control.
- Connect with CDKL5-specific caregiver communities and registries. Because CDD is extremely rare and combines epilepsy with a distinct developmental and behavioral pattern, condition-specific caregiver networks and patient registries often provide more directly relevant guidance than general epilepsy or developmental-delay resources.
- Ask about circadian and sleep-specific strategies, not just sedatives. Caregiver reports describe disrupted nighttime wakefulness patterns in CDD that may reflect circadian rhythm disruption rather than simple insomnia, so ask whether your care team has considered circadian-focused approaches alongside standard sleep medications.
The Hidden Burden: Sleep Disruption and Family Wellbeing
A 2026 study drawing on caregiver-reported data from 258 individuals in the International CDKL5 Disorder Database found that sleep disturbance affects most families, with insomnia, nighttime wakeful episodes caregivers described as “night parties” (possibly reflecting disrupted circadian rhythms), and daytime sleepiness among the most common concerns. Constipation was linked to more than twice the odds of significant sleep-onset and sleep-maintenance problems, while daily seizures were linked to greater sleep-breathing disturbance. Interestingly, patients 18 and older had meaningfully better sleep-onset and maintenance scores than those ages 3 to 5, suggesting this specific sleep difficulty may ease somewhat as children get older, even as other challenges persist. The same 2026 observational study that tracked 112 patients also measured quality of life directly, finding that overall quality-of-life scores ranged from 53% to 64%, with independence the most affected domain of all. Taken together, these findings point to modifiable, treatable contributors, constipation and medication side effects among them, that can meaningfully improve sleep and overall family wellbeing even when seizures themselves remain difficult to control.
Beyond Seizure Control: New Treatment Directions
A 2026 open-label study gave highly purified cannabidiol (CBD) to nine patients with CDD (all female, median age 10 years, ranging from 1 to 24 years old) and found that a more than 50% reduction in seizures occurred in eight of the nine patients at three months, though this effect faded over time, with only one of the eight remaining patients still showing that level of reduction after 12 months. Yet caregivers reported benefits that had little to do with seizure counts: seven of the nine patients showed improved alertness and engagement, three showed improved motor skills, and two showed improved sleep and constipation. Notably, most families chose to continue CBD even after its seizure-reducing effect wore off, because they valued these broader improvements, a sign that seizure frequency alone does not capture what matters most to families. A separate 2026 mouse study points toward why earlier, more targeted intervention might change outcomes more fundamentally: CDKL5-deficient mice showed reduced activity of KCC2, a transporter central to a developmental shift in how brain cells respond to a key signaling chemical. Treating mice with a KCC2-activating drug during a specific early window after birth not only reduced seizures at the time, but also left the mice with reduced seizure susceptibility and improved cognitive and behavioral function once they reached adulthood, suggesting that targeting CDKL5's underlying biology during a critical developmental window could reshape a child's broader trajectory, not just manage seizures in the moment.
Practical Tips for Families and Caregivers
- Ask your care team to address constipation proactively. Given its documented link to more significant sleep disturbance in CDD, treating constipation early and consistently may meaningfully improve both sleep and daytime functioning, even when seizures remain hard to control.
- Look beyond seizure frequency when judging whether a treatment is working. Research shows caregivers often value improvements in alertness, mood, sleep, and engagement as much as seizure reduction, so track these changes explicitly and share them with your care team, even if seizure counts alone look unchanged.
- Ask whether a circadian-rhythm approach could help with nighttime wakefulness. Because disrupted nighttime wakeful periods in CDD may reflect circadian disruption rather than ordinary insomnia, ask your care team whether circadian-focused strategies are worth exploring alongside standard sleep medications.
- Don't expect developmental progress to track seizure control. Because CDKL5 shapes brain development independently of seizure activity, keep investing in developmental, communication, and physical therapies regardless of how seizures are currently responding to treatment.
- Give yourself credit for the work sleep disruption adds to caregiving. CDD's sleep challenges are well documented and are not a sign you are doing something wrong; connecting with other CDKL5 caregivers, even briefly, can offer practical strategies and support that general resources often don't.